Oncology

Latest News

The investigators found that patients with SCLC and cachexia were more likely to have problems with treatment. | Image credit: appledesign - stock.adobe.com

Cachexia Worsens Prognosis in Older Patients With Advanced SCLC

July 9th 2025

Older patients with small cell lung cancer and significant weight loss were more likely to experience dose interruptions than patients with cachexia.

Insurance gaps | Image Credit: iQoncept-stock.adobe.com

Insurance Gaps Threaten Cancer Treatment Success

By Maggie L. Shaw

July 7th 2025

Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski

Decline in SCLC Incidence Expected to Accelerate Through 2050

By Jared Kaltwasser

June 29th 2025

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com

Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

By Kimberly Rath, PharmD

June 27th 2025

Gender rights | Image Credit: © Nadzeya-stock.adobe.com

Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care

By Maggie L. Shaw

June 23rd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

July 12th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

July 12th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

December 7th 2015

Do Hematologists Believe APMs Afford Fair Value? An Open Discussion at ASH

Surabhi Dangi-Garimella, PhD

On the second day of the annual meeting of the American Society of Hematology, physicians got together to discuss the real-world needs of alternate payment models in hematology.

December 7th 2015

Study Shows Academic Hospitals More Adept at Caring for ALL Patients

Surabhi Dangi-Garimella, PhD

During a health outcomes session on the second day of the American Society of Hematology meeting, data presented from a study conducted at the University of Nebraska Medical Center suggested that the site of care bears a significant influence on the outcomes of patients with acute lymphoblastic leukemia.

December 6th 2015

Importance of Patient-Reported Outcomes and Quality-of-Life Measures in Myeloid Disease

Surabhi Dangi-Garimella, PhD

Two posters presented at the annual meeting of the American Society of Hematology discussed patient-reported outcomes measures and quality-of-life indicators as supportive tools for treatment in individuals being treated for acute myeloid leukemia and myelodysplastic syndrome.

December 6th 2015

How Do You Develop, and Successfully Incorporate, PROs in Hematology? Experts Chime in at ASH

Surabhi Dangi-Garimella, PhD

Presenters at an education session, titled Patient-Reported Outcomes in Hematology, addressed the importance of embracing the patient perspective in healthcare delivery, on the second day of the annual meeting of the American Society of Hematology, being held December 5-8, in Orlando, Florida.

December 5th 2015

Experts Share Concepts of Quality Measures and Pay-for-Performance at the Annual ASH Meeting

Surabhi Dangi-Garimella, PhD

At the annual meeting of the American Society of Hematology, providers brooded over implications of quality measures and how they will influence clinical practice in the coming years.

December 5th 2015

New Hematology Drugs: Progress and Challenges Discussed at the 57th ASH Meeting

Surabhi Dangi-Garimella, PhD

An early session on the first day of the annual meeting and exposition of the American Society of Hematology, being held December 5-8, 2015, in Orlando, Florida, saw presentations on the promise of newly approved hematology/oncology agents, in addition to the challenges that clinicians face in treating patients with these drugs.

December 4th 2015

5 Things to Look for at the Annual Meeting of the American Society of Hematology

Surabhi Dangi-Garimella, PhD

As the annual meeting of the American Society of Hematology kicks off on Saturday, December 5, 2015, a lot of new clinical data will be presented, practice-changing treatments will be introduced, and new healthcare policies will be discussed.

December 3rd 2015

What Is the True Financial Impact of Prescription Medications? Advera Health Explains

Surabhi Dangi-Garimella, PhD

In a study published in the Journal of Managed Care & Specialty Pharmacy, the authors present a rating system that includes downstream costs following treatment to estimate the real-world financial impact of the drug.

December 2nd 2015

Antidepressant Use Safe for Stress in Breast Cancer, Says Kaiser Study

Surabhi Dangi-Garimella, PhD

An exhaustive study published by Kaiser Permanente in the Journal of the National Cancer Institute has confirmed that antidepressants do not cause recurrence in breast cancer patients treated with tamoxifen.

December 2nd 2015

Stress a Significant Determinant of Breast Cancer Outcomes

Surabhi Dangi-Garimella, PhD

A study published in the journal Breast Cancer Research and Treatment cognitive-behavioral stress management introduced early in care management can improve breast cancer outcomes.

December 1st 2015

Consider Race Prior to Neoadjuvant Breast Cancer Chemotherapy, Oncologists Recommend

Surabhi Dangi-Garimella, PhD

A new study suggests that a poor response to neoadjuvant chemotherapy-frequently administered to black, Hispanic, and Asian women-could dictate survival rates in breast cancer.

November 30th 2015

Ted Okon Outlines the Importance of Payer-Provider Dialogues

The current dialogue occurring between payers and providers is critical in today's healthcare environment, and it's an interaction that certainly was not happening just 5 or 6 years ago, according to Ted Okon, executive director of the Community Oncology Alliance.

November 30th 2015

FDA's Decision on Elotuzumab Further Expands Options in Multiple Myeloma

Surabhi Dangi-Garimella, PhD

Following the approval of daratumumab earlier this month, multiple myeloma patients now have another opportunity to combat the disease: elotuzumab.

November 30th 2015

Pharmaceutical Advertising Increased Prescription Drug Utilization, Study Reports

Surabhi Dangi-Garimella, PhD

Relaxed direct-to-consumer advertising restrictions for drugs by the FDA in 1997 has precipitated an increase in prescription drug utilization, not just among Medicare enrollees, but also among non-elderly users.

November 27th 2015

Dr Kavita Patel Outlines How Oncology Is Ripe for Delivery Reform

Oncology, like primary care, is ripe for delivery reform, but it has remained stuck in a fee-for-service mindset, said Kavita Patel, MD, fellow in economic studies and managing director at Brookings Institution.

November 27th 2015

American College of Physicians Recommends More Use of Generic Medications

Surabhi Dangi-Garimella, PhD

The American College of Physicians has published a paper in the Annals of Internal Medicine that advices clinicians to prescribe generic drugs whenever possible.

November 25th 2015

At Thanksgiving, Take Time to Collect Family Medical History

Mary K. Caffrey

Waiting until there's a cancer diagnosis or other crisis is not the time to be taking the family's medical history. Testing companies and genetic counselors encourage families to share information when they are all in one place.

November 24th 2015

Joy Larsen Haidle Discusses How Patients Should Use Genetic Tests

Patients considering using a genetic test should meet with a genetic counselor first to get a better understanding of the patient's goal for getting the test done and determine the likelihood that a test might be useful, explained Joy Larsen Haidle, MS, CGC, president of the National Society of Genetic Counselors.

November 24th 2015

Another First for Nivolumab: Approved as Frontline for BRaf Wild Type Melanoma

Surabhi Dangi-Garimella, PhD

The approval follows 5 months after Bristol-Myers Squibb submitted phase 3 results of the Checkmate-066 trial for FDA review.

November 23rd 2015

Nivolumab Approved for Third Indication: Advanced Renal Cell Carcinoma

Surabhi Dangi-Garimella, PhD

Two months after being granted a Breakthrough Therapy designation by the FDA for metastatic renal cell carcinoma (mRCC), nivolumab was today approved by regulators for treating mRCC patients who have failed a certain type of prior therapy.

November 23rd 2015

Decade-Long Screening Efforts Bear Fruit for CRC Screening in New York City

Surabhi Dangi-Garimella, PhD

A state-led program, initiated in 2003, has nearly doubled screening colonoscopy rates in New York City and also eliminated racial and ethnic disparities in the process.

November 22nd 2015

Staying Focused on the Cancer Patient, Amid Rising Drug Costs and New Payment Models

Giving cancer patients what they want and need is the goal, but getting there isn't easy, according to healthcare experts who took part in Patient-Centered Oncology Care 2015, presented November 19-20, 2015, by The American Journal of Managed Care. Drug costs demand difficult conversations about value, and changes in the law require oncologists to learn whole new ways to be paid.

November 21st 2015

As Prospect of Risk for Doctors Looms, Cost Conversation Shifts in Cancer Care

Mary K. Caffrey

Three years after Memorial Sloan Kettering Cancer Center refused to add Zaltrap to its formulary due to cost, value is part of the national conversation in cancer care. The new question is what will happen when physicians assume risk.

November 21st 2015

Dr Scott Gottlieb Worries About More FDA Regulation in Diagnostic Testing

If the FDA steps in to regulate laboratory-developed tests, it will slow down innovation, add costs to the development of the product, and likely decrease the number of tests that come out, but the public health benefits of increased oversight might be worth it, said Scott Gottlieb, MD, resident fellow at the American Enterprise Institute.

November 21st 2015

Dr Peter Bach Examines the Problems of the 340B Drug Pricing Program

While the 340B Drug Pricing Program was designed to help facilities that take care of impoverished patients with low-cost drugs, what the program has morphed into is almost the opposite of what it was intended to do, said Peter Bach, MD, MPP, director of Memorial Sloan Kettering's Center for Health Policy and Outcomes.

November 21st 2015

Are PBMs the Answer to Managing the High Cost in Oncology Care?

Surabhi Dangi-Garimella, PhD

A pharmacist who engages in formulary decisions, a medical director for population management for a private health exchange, and an innovations leader at a pharmacy benefit manager, took to the podium at the Patient-Centered Oncology Care meeting on November 20, 2015, to discuss cost-saving strategies in oncology and whether benefit managers can play a role in reining-in some of these costs.

November 20th 2015

End-of-Life and Palliative Care to Be Discussed During AJMC's November 24 Tweetchat

During a tweetchat on November 24 at 3:30 pm EST, Amy Berman, RN, BS, and Judith R. Peres, LCSW-C, will discuss patient-centered care, palliative care, and end-of-life care.

November 20th 2015

Dr Bruce Quinn Describes How Europe and the US Regulate Diagnostic Tests Differently

While the FDA could regulate diagnostic tests the way they are in Europe-through simple verification that the test is accurate-the FDA has not chosen to do that and comes closer to requiring clinical utility, explained Bruce Quinn, MD, PhD, senior director at FaegreBD Consulting.

November 20th 2015

Dr Julie Vose Weighs in on Value Calculators, MACRA

Julie M. Vose, MD, MBA, FASCO, president of the American Society of Clinical Oncology (ASCO), and keynote speaker at this year's Patient-Centered Oncology Care meeting, discusses addressing cost of care, using value calculators, and the Medicare Access and CHIP Reauthorization Act.

November 20th 2015

What We're Reading: CMS Wants to Penalize Doctors for Prostate Tests

AJMC Staff

What we're reading, November 20, 2015: CMS wants to penalize doctors for ordering routine prostate-cancer screening tests; lawmakers, patients, and advocates call for head of Drug Enforcement Agency to be fired; and specialty drug costs exceed household incomes.

...

116 117 118 119 120 121 122 123 124

...

186 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions